| April 12,
2007--QIAGEN North American Holdings, Inc., a
subsidiary of QIAGEN N.V., is offering approximately $34
million in a planned merger with eGene, Inc.
QIAGEN expects the transaction to add revenues of
approximately $2 million in the second half of 2007 and
roughly $7-9 million in sales for the full year of 2008.
eGene's offerings will
supplement QIAGEN's sample and assay technologies. eGene
has developed a multi-channel sample separation and
analysis technology for nucleic acids. Its consumable
cartridges are designed for applications in the molecular
diagnostic and research markets, including formats
addressing the Human Leukocyte Antigen testing market, genetic
testing including microsatellite analyses, DNA post-PCR
separation and analysis at different resolutions, and RNA
integrity quality control.
The HDA-GT12 Genetic Analyzer integrates automatic sample
loading, separation, and data analysis.
The merger is expected to
close in the third quarter of 2007; eGene would then
become a fully owned subsidiary of QIAGEN North American
Holdings. QIAGEN |
